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Rapid advances in clinical technologies, detection sensitivity and analytical throughput have 
delivered a significant expansion in our knowledge of prognostic and diagnostic biomarkers in 
many common infectious diseases, such as Tuberculosis (TB). During the last decade, a significant 
number of approaches to TB diagnosis have been attempted at Point-of-Care (PoC), exploiting a large 
variation of techniques and materials. In this work, we describe an electronics-based Enzyme-Linked 
ImmunoSorbent Assay (eELISA), using a Lab-on-a-Printed Circuit Board (LoPCB) approach, for TB 
diagnosis based on cytokine detection. The test relies upon an electrochemical (amperometric) assay, 
comprising a high-precision bioinstrumentation board and amperometric sensors, produced exclusively 
using standard PCB manufacturing processes. Electrochemical detection uses standard Au and Ag 
electrodes together with a bespoke, low-power, multichannel, portable data-acquisition system. We 
demonstrate high-performance assay chemistry performed at microfluidic volumes on Au pads directly 
at the PCB surface with improved limit of detection (~10 pg/mL) over standard colorimetric ELISA 
methods. The assay has also been implemented in plasma, showing the utility of the system for medical 
applications. This work is a significant step towards the development of a low-cost, portable, high-
precision diagnostic and monitoring technology, which once combined with appropriate PCB-based 
microfluidic networks will provide complete LoPCB platforms.
The concept of a PoC laboratory is not new, however it remains an interesting and challenging aspect of clinical 
diagnosis1. The benefits of PoC laboratories are multidimensional, and in addition to direct PoC applications 
provide convenient means to analyse biomarkers in populations distant from hospitals or clinical laboratories. 
Moreover, with the sustained expansion of the Internet of Things (IoT), PoC platforms can easily connect to core 
laboratories and request any required data or processing support. Over the last decade, the rapid diagnosis of TB 
in both developed and developing countries has benefited from the cost-effectiveness of various POC platforms. 
However, TB remains one of the world’s deadliest diseases, with one third of the world’s population affected. 
Globally, in 2014, 9.6 million people became infected, resulting in 1.5 million TB-related deaths2.
For PoC devices, the obvious route is to port standard immunochemical assays from the laboratory or “assay 
track” into PoC diagnostic tools3–10. However, certain barriers have prevented wide scale application of PoC tech-
nologies. Current assay protocols often require colorimetric detection and thus bulky spectroscopic equipment, 
and bespoke manufacturing has been required for complex microfluidics and pumps11, 12. Versatility has also been 
an issue; numerous different systems for numerous different assays would clearly not be appropriate for PoC diag-
nostics as the physician must have a high level of confidence in their tools, gained through repeated application.
There are many reasons why PoC diagnostics have yet to become mainstream among developed economies. 
Not least are issues in the transfer of complex technologies such as pumps, fluidics and sophisticated detection 
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cells and electrodes to commercial manufacturing processes13. To address this issue, our philosophy is to develop 
highly sensitive assay technology using exclusively commercial PCB manufacturing processes. Our industrial 
partner, Newbury Electronics, manufacture the prototype PCBs to include fully embedded microfluidic archi-
tecture and Au/Ag amperometric electrodes at the PCB surface. This commercially manufactured PCB approach 
allows the production of completely functional amperometric PCB-based sensing units for a few pence each 
(excluding the electronics unit and the chemical reagents). Moreover, our design and technology allows any assay 
adapted to this system to be performed on the standard PCB unit simply by switching reagents14–16.
In this publication it is our intention to demonstrate the transition of electrochemical analysis techniques to 
commercially manufactured surfaces. We present a detailed investigation of the integration points necessary to 
develop working biodetection systems and progress to a fully working device in partnership with existing manu-
facturing technologies. We show entirely novel PCB designs, improving sensitivity over commercial colorimetric 
and published amperometric systems, combined with detailed analyses of pre-calibration performance with ref-
erence specifically to clinical diagnostics.
The assay we have implemented is a commercially available anti-Interferon gamma (IFNγ) ELISA from R + D 
Biosystems. IFNγ is a pro-inflammatory cytokine with a central role in innate and acquired immunity. In the 
clinical laboratory interferon gamma release assays (IGRA’s) are used routinely in at risk populations to diag-
nose latent TB infection (LTBI)17. These commercial assays are based on the principle that T-cells in TB patients 
respond to re-stimulation with TB specific antigens (CFP-10, ESAT-6 and TB7.7) by producing IFNγ. IFNγ pro-
ducing T- cells are quantified by ELISAspot (T-Spot TB Oxford Immunotec) or IFNγ secretion detected by ELISA 
(QuantiFERON-TB Gold In-Tube, Cellestis)18, 19. However, IGRA’s are time consuming, requiring 12+ hours 
pre-incubation of blood with TB antigens before blood separation. Furthermore, QuantiFERON test samples are 
usually batch tested for cost-effectiveness, increasing handling times to up to or over one week.
Previously published research work from our group detailed early results using PCB-based assay technology 
for the detection of IFNγ using a commercial potetiostat and provides comparative results from other colori-
metric and amperometric endeavours20. We now demonstrate improved assay sensitivity over both previously 
published systems and standard colorimetric methods. In addition, we introduce and apply our own, bespoke, 
custom-made data acquisition electronics for the PCB-sensors’ read-out. We characterise the sensor performance 
and identify automated PoC device relevant measurement protocols, in addition to providing individual assay, 
and individual sensor performance data. Assays are independently characterised by Surface Plasmon Resonance 
(SPR), and all electrochemical measurements are conducted using bespoke in-house portable electronics. We also 
demonstrate assay functionality in a blood plasma matrix to reflect the final intended application.
Our commercial PCB manufacturing technologies will lead to the development of a lightweight, low-cost 
amperometric detection unit, manufactured using standard commercial processes to include embedded 
microfluidics and multi-channel amperometric sensing. The assays are based on electrochemical detection of 
3,3′,5,5′-Tetramethylbenzidine (TMB), a common colorimetric reporter reagent in standard ELISAs. We demon-
strate assay component ligand binding by standard SPR to allow comparison to other common assay systems and 
to evaluate binding of capture antibodies (Cysteine modified ScFv) via thiol link to a Au surface. We show TMB 
substrate conversion dependent amperometric signal elevation with a linear correlation, and we demonstrate 
full assay performance in both aqueous and plasma matrices. This PCB technology is simple and many industry 
standard diagnostic assays could be adapted to this assay platform.
Results
Assay Component Analysis. With the intention of producing a complete hand-held biosensor for the 
detection of IFNγ, the detection range was focused on the clinically relevant range associated with Mycobacterium 
tuberculosis infection. An existing colorimetric diagnostic assay system was adapted to operate with reduced vol-
ume, with assay components localised on Au sensor surfaces. The original colorimetric assay system is produced 
by R + D Biosystems and is capable of identifying IFNγ in blood plasma samples with a published detection limit 
of 15 pg/mL. This commercial system uses standard ELISA analysis of 100 μL volumes in standard 96-well plates. 
The modified assay operates in 10 μL volume on a Au surface with one major component substitution and further 
reagent adjustments. Assay changes are illustrated in Fig. 1.
Initially we characterised antibody-target interaction by SPR. Capture antibody α IFNγ Fab′-3Cys-6His) was 
immobilised on a Au sensor chip surface. Covalent binding was achieved via thiol linkage to sulfhydryl groups 
present due to the modified inclusion of Cysteine residues. This binding step was characterised by SPR, although 
it must be noted that surface linkage in SPR experiments is conducted under flow, while in the case of our proto-
type sensor surfaces the linkage step is static. We flowed a series of titrated IFNγ samples over the surface of the 
chip and recorded changes in resonance units (RU) before and after sample flow. The binding characterisation 
plot is shown in Fig. 2. A standard sigmoid binding curve is produced indicating standard 1:1 binding kinetics. 
Primarily these results demonstrate that we are able to bind our Cysteine modified Fab′ antibodies passively to a 
Au surface and then conduct a quantitative assay.
Sensor Characterisation. The major innovation in our PCB-based hand-held assay is the use of standard 
low-cost commercial manufacturing techniques. As with electrical connections and microfluidics our electrode 
surfaces are laid down as part of this process. A thin layer of Cu foil is laminated to the FR4 PCB substrate with 
heat and adhesive. Then appropriate electrical connections (tracks) and electrode pads are patterned by etching 
the Cu layer. Next a Au layer is plated onto the Cu surface, fixed by the copper primer which determines the 
final distribution of Au. In general, electrochemical detection uses highly refined and precisely manufactured 
electrodes with surface area, volume and geometry designed to optimise electrochemical detection within the 
specific framework provided by the measurement system. The detection process can then be optimised through 
electrode design. In order to achieve good precision in detection with titrated samples separated neatly within 
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appropriate standard deviations, a relatively high electrode bias was used (−300 mV), as determined by cyclic 
voltammetry (CV). This electrode bias provides sufficient resolution between titrated samples, without damaging 
the electrode surface, since very high biasing voltages may lead to accelerated corrosion of the electrodes due to 
redox reactions.
To optimise consistency in signal magnitude between sensors, we characterised sensor activity across 
extended measurement times to establish appropriate measurement points and periods. 1 M Sodium Chloride 
(NaCl) was used as the analyte electrolyte and measurement was performed using five different sensors over an 
extended time period (400 s). This analysis was conducted without voltammetric surface preparation by CV. As 
it can be seen in Fig. 3, our results showed considerable variability, which would be lead to large errors in quan-
titative amperometric measurement. However, after 200 s sensor readings converged and signal drift gradually 
decreased until a tight signal grouping was observed at around 400 s. All measurements presented herein were 
acquired following a similar electrode conditioning period. The final hand-held PoC sensor design will have 
access to fluidic control with internal reference standards to calibrate signal levels between sensors.
Electrochemical TMB Quantification. The amperometric detection methods used in this investi-
gation are often referred to as second generation amperometry21. The system directly detects charge carrier 
Figure 1. Biological components of the original colorimetric diagnostic assay system (R + D Biosystems) and 
the converted assay been used for the eELISA detection method.
Figure 2. Characterisation of antibody-target interaction using SPR. A standard sigmoid binding curve is 
produced indicating standard 1:1 binding kinetics.
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concentration through measurement of total current magnitude rather than utilising electrochemical reactions 
directly at the electrode. The assay components required for integration therefore include only a charge carriage 
reporter molecule within a relatively low conductivity electrolyte. A very common colorimetric reporter system 
in standard diagnostic ELISAs is TMB. Reporting functionality is achieved through enzymatic conversion to the 
corresponding diimine product by the horseradish peroxidase enzyme (HRP). TMB is a colourless liquid, while 
the resulting product is bright blue. Hydrogen peroxide (H2O2) is required as an enzymatic co-factor and is con-
sumed in the conversion process providing free hydroxyl ions to the solution22. Therefore, this system delivers 
two charge carriers, a TMB diimine product and free hydroxyls, both of which are theoretically electrochemically 
active. Our assay system is optimised to detect the TMB product due to the more reactive and transient nature of 
hydroxyl ions, providing a higher consistency in assay-dependent reporter concentration over time.
To establish detection ranges and to prove the concept of TMB we first compared amperometric measure-
ments with colorimetric, using a range of TMB product concentrations. Due to the possibility of the enzymatic 
component skewing returned amperometric signal we made efforts to minimise electrochemical contributions 
from this source. Solutions of variable TMB product concentrations were made by adding a measured quantity 
of HRP to a stock sample of TMB substrate. 200 μL aliquots were then removed at various time-points following 
reaction initiation by addition of HRP. The reaction was stopped by addition of 20 μL of 1 M HCl, attenuating 
enzyme activity. A lower pH also reduces the ionic interaction between associated pairs of the diimine product 
changing the colorimetric absorption maxima from 650 nm (blue) to 450 nm (yellow). The TMB product was 
then assessed both amperometrically and colorimetrically. Nine samples were measured using three sensors. The 
results shown in Fig. 4 demonstrate a clear correlation between TMB product concentration as determined by 
time of reaction, and amperometric and colorimetric signals. Both within sensor variability and between sensors 
variability fall within acceptable ranges.
Figure 3. Transient sensor behaviour using a TMB electrolyte (OD 0.5 by colorimetric analysis). All sensors 
converge to an equilibrium point after a threshold time value (>400 s), which has been selected as a starting 
point for each measurement herein.
Figure 4. Comparison of amperometric and colorimetric detection of TMB product concentrations. A range 
of TMB product concentrations were achieved by allowing a range of enzymatic conversion times using a single 
HRP enzyme concentration. Results were obtained using three different amperometric sensors, however, all 
colorimetric results were obtained using the same colorimetric quantification apparatus (Promega Glomax).
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Amperometric and colorimetric signals are broadly comparable (see Fig. 4), although the amperometric sys-
tem does not show signal extinction at lower concentration ranges as seen in the colorimetric analyses. Signal 
extinction occurs where there are insufficient concentrations of reporter component to register a signal. This 
effect is more thoroughly characterised in the following sections, where we performed full assay chemistry to 
measure TMB concentrations from very low target concentrations. These results show that amperometric detec-
tion would be as effective as colorimetric for many diagnostic applications. They also demonstrate the suitability 
of our commercially manufactured PCB-based technology to this task.
Assay at PCB Surface. The PCB-based detection system uses Au surface to capture and immobilise anti-
body fragments via Cysteine (thiol) linkage. Three Cysteine residues are conjugated to Fab′ antibody fragments 
to yield sulfhydryl groups for thiol linkage to the Au surface. The assays were performed at the PCB surface, 
with proteins immobilised on Au-coated Cu pads. Fluid wells were cut from PMMA and fixed to the PCB sur-
face. Samples were measured electrochemically by removal to a sensor well as described for TMB detection. 
Colorimetric values were obtained by measuring absorbance at 450 nm using a nanodrop spectrophotometer.
Three identical assays were performed and measured using three different sensor surfaces. The results in 
Fig. 5 show that IFNγ detection target levels correlate linearly with the amperometric signal. This assay was able 
to detect IFNγ at a range of concentrations broadly reflecting the clinically relevant range measured in IGRA’s for 
latent TB infection (10–2000 pg/mL). Linear correlation extends to lower concentrations for the amperometric 
detection system, where signal extinction is observed for colorimetric analysis.
High Sensitivity Assay. To investigate our observation that amperometric detection of TMB product is 
more sensitive than the standard colorimetric system we performed a second assay using lower concentrations of 
IFNγ (10–120 pg/mL), prepared using a shallower dilution scheme. Assay sensitivity for the colorimetric system 
was determined to be 35 pg/mL, while no sensitivity limit has been effectively demonstrated here for ampero-
metric detection. It should be noted that the lowest concentration sample displayed in Fig. 5 is a blank (0 pg/mL 
Figure 5. Amperometric assay experiment using the modified assay components measured with the PCB-
based sensor. (A) Amperometric measurement using the PCB-based sensor and in-house bioinstrumentation 
platform. (B) Colorimetric validation of the experimental results shown in (A). (A,B) Show three discrete 
IFNγ titration assays as described in Fig. 1 with amperometric values measured on three discrete sensors and 
colorimetric values measured on one sensor (Promega Glomax). (C) Amperometric data for low concentration 
IFNγ assay using Log1.5 analyte dilutions. (D) Colorimetric verification of the experimental results shown 
in (C). Although the colorimetric system demonstrates a LoD of 35 pg/mL for the specific experiment, the 
amperometric LoD is significantly lower at ~10 pg/mL. Judging from the obtained current ranges and given the 
characteristics of the bioinstrumentation board, these measurements predict that the LoD could potentially 
reduce even more in the final optimised system.
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IFNγ) and shows the baseline signal, suggesting that the concentrations applied in this experiment are close to 
the sensitivity level for amperometric detection as part of this assay system. We note that the colorimetric assay 
is un-optimised, bespoke buffers are supplied with the R + D Biosystems kit upon which this assay is based, 
these have not been used for this assay. However, our conclusion is that our amperometric system can effec-
tively detect lower levels of TMB product than the colorimetric systems employed herein irrespective of specific 
assay chemistry. We show that our amperometric system can detect TMB product levels that cannot be detected 
colorimetrically thus, suggesting that sensitivity can be increased globally for standard colorimetric diagnostic 
procedures by replacement with amperometric detection. Currently clinical diagnosis of TB by IFNGR assay can 
only provide diagnosis by recognition of an elevated level of IFNγ as normal non-clinical serum levels of IFNγ are 
not detectable. The improved sensitivity we demonstrate in lower concentration ranges could provide significant 
improvements to diagnostic certainty.
Assay in Plasma Matrix. In order to demonstrate that our assay system is suitable for the intended medical 
application we demonstrate that it is functional in a plasma matrix. As IFNγ detection in TB diagnostics must be 
performed at very high sensitivities (10–1000 pg/mL approx.) measurement samples are likely to be undiluted. 
Therefore, we demonstrate our assay procedure using IFNγ-spiked human plasma. The obtained results of Fig. 6 
are broadly similar to those obtained in the parallel assay run in PBS. We conclude that plasma is an acceptable 
matrix for our assay and detection system.
Discussion
This work demonstrates components for a framework system for PoC diagnostic platform using low-cost com-
mercially manufactured PCB components (summarised in Figs 7 and 8). As an imminent future step, we seek 
to dramatically reduce the cost of complex microfluidics by integrating microfluidic channel fabrication into 
standard commercial PCB manufacturing processes. As such this work should be viewed with reference to other 
Figure 6. Three discrete IFNγ titration assays were performed in a plasma matrix. TMB reporter solutions 
harvested from each were applied to a different sensor to produce the three measurement series. Therefore, 
this analysis demonstrates the additive variabilities from assay steps, electrochemistry, and between sensor 
measurements.
Figure 7. (A) A three-dimensional representation of the fabricated prototype PCB-based biosensor and (B) the 
HRP-catalysed oxidation of TMB.
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published aspects of this endeavour of our research group, such as our recently developed PCB-based passive 
microfluidic induction and flow systems, and pressure-driven microfluidic serial dilution networks12. The work 
we present here demonstrates functionality in the molecular and electronic aspects of our system (eELISA), 
including assay technology and sensitivity, sensor characterisation and reporter signal transduction.
The assay we modified to function within our amperometric system is a high sensitivity sandwich ELISA 
for IFNγ detection produced commercially by R + D Biosystems (see Fig. 1). We have demonstrated assay 
functionality using a capture antibody specifically modified by papain cleavage to yield Fab′ fragments, and 
tri-cysteinylation to provide sulfhydryl groups for thiol linkage to an Au surface. The suitability of this immobi-
lisation technique to Au is shown through SPR analysis (see Fig. 2). In order to assess our system performance 
we isolated the TMB reporter system and assessed amperometric and colorimetric measurements ex-assay. Three 
discrete TMB product concentration series were measured using our in-house electronics, on each of three dif-
ferent sensors. Standard deviations show a significantly greater range of error than colorimetric analysis when the 
same sample was measured, demonstrating a greater variability in measurement accuracy with the amperometric 
system, although error is still confined within acceptable limits (see Fig. 4). For example, in Fig. 4, assay point 5 
of sensor 1 shows the highest standard deviation within the normal assay range, although this standard deviation 
range does not overlap with the standard deviation ranges of the immediately higher and lower TMB product 
concentrations. Between-sensor error ranges will be eliminated by standard sensor calibration protocols such 
as using a reference sample and measuring the difference between this and the analytical sample. As previously, 
we note that the colorimetric comparison presented here is not a true comparison as only a single standardised 
colorimetric sensing system is available.
With respect to the IFNγ assay, the results in triplicate of Fig. 5 demonstrate linear signal progression with 
increasing concentrations of TMB product as determined by enzymatic conversion time. Unique assay points of 
equal IFNγ concentration show some distribution across a range of μA values demonstrating a requirement for 
individual sensor calibration within the final device but confirming IFNγ concentration-dependant signal mag-
nitude suitable for IFNγ quantification with these assay components. We note that no comparative assessment 
Figure 8. (A) A three-dimensional representation of the custom-made electronic board for sensitive 
amperometric measurements. (B) The individual compartments of the electronic board and their approximate 
location on (A).
www.nature.com/scientificreports/
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of standard colorimetric measurement is available as the colorimetry shown is produced using a single sensing 
device. Due to the non-uniform nature of our sensing surfaces when compared to standard commercial (and 
much more expensive) electrochemical electrodes we assessed sensor performance over an extended time period 
to establish appropriate measurement points and periods. Our data show that while signals are initially very vari-
able, at 400s they converge to a tight grouping at around 140–160 μA. Results presented herein were thus recorded 
at 400 s across a period of 30 s.
The previous observations made during TMB product detection analyses led to the suggestion that our amper-
ometric detection system may allow identification of even lower concentrations of TMB product than equivalent 
colorimetric detection (data not shown). For this reason we conducted a very-low-concentration IFNγ assay 
using a shallower IFNγ target dilution scheme. We observe ostensible colorimetric signal extinction at 24 pg/mL 
of IFNγ, while amperometric limit of detection (LoD) appears to be at IFNγ concentrations of ~10 pg/mL. Finally, 
the experiment in Fig. 6 performed in a plasma matrix verifies the hypothesis that plasma is an acceptable matrix 
for our proposed assay and detection system.
Given the very widespread application of standard colorimetric analyses in clinical diagnostic laboratories 
and hospitals we feel the provision of a reporter detection system able to significantly increase standard assay 
sensitivities would constitute a medically and commercially significant output. It is noteworthy that the detection 
system alone can be applied to standard ELISA analysis without altering assay technology that has already been 
extensively validated through both FDA product confirmation and years of clinical diagnostic application. This 
is in addition to the provision of a comparable hand-held assay system. The next stage of this ongoing research 
and development project will be to integrate passive fluidics to include serial dilution and fluid induction12 and 
complete development of fluidic channels to allow switching between analyte and reference samples and achieve 
reliable signal calibration. We will then demonstrate full diagnostic capability and statistical performance verifi-
cation through the measurement of a statistically significant cohort of clinical samples.
Conclusions
We demonstrate an exploded assay system to be considered in concert with passive microfluidic induction and 
sample handling systems we have developed and published elsewhere12. Our systems are fabricated using stand-
ard commercial PCB manufacturing techniques which deliver low-volume microfluidic channels, and inte-
grated sensor and assay surfaces. We combine the advantages of low-cost lateral flow diagnostics with high-value 
high-sensitivity microfluidic PoC systems. We have demonstrated applicable assay chemistry by converting an 
industry standard high-sensitivity IFNγ assay to our low volume integrated assay and sensor pads. We have fur-
ther demonstrated improved detection sensitivity of our amperometric system when compared to the standard 
colorimetric equivalent theoretically allowing sensitivity improvements in all TMB-reporter colorimetric assay 
systems. We have also characterised sensor performance and measurement point and period. Next we intend to 
assemble a working prototype with full microfluidics and demonstrate a fully automated hand-held PoC assay 
system.
Materials and Methods
Surface Plasmon Resonance. Anti-IFNγ Fab′(Cys)3 antibodies were diluted to 20 μg/ml in PBS. The sam-
ple was flowed across a one channel of standard Au SPR chip (25 μL/min, 5 minutes), while the other channel was 
concurrently treated with 100 mM HEPES system buffer to act as a measurement blank. A Log2 IFNγ titration 
was prepared in PBS with a top concentration of 4 ng/mL. Samples were flowed across the prepared chip sur-
face channels (25 μL/min, 4 minutes) and RU spectra recorded. Chip surfaces were regenerated between sample 
measurements via pH desorption using 100 mM Phosphoric acid (25 μL/min, 4 minutes). Displayed values (see 
Fig. 2) were prepared by subtracting blank values from the reference channel from the measurement channel 
and recording the difference in RU between before sample flow induction and after sample flow cessation and 
observed equilibration.
TMB Detection. Samples of varying TMB product concentration were prepared by adding 1 μL 1 mg/mL 
HRP (R + D Biosystems) to 10 mL of TMB substrate (1 TMB tablet (Sigma Aldritch T5525) in 10 mL de-ionised 
water and 5 μL 30% (by volume) H2O2). 1 mL aliquots were then removed at recorded time-points and the enzy-
matic reaction stopped immediately in the removed aliquot by addition of 100 μL 1 M HCl. 40 μL samples were 
measured in bespoke PCB-based cells consisting of an internally fabricated PMMA well (50 μL total volume) over 
two Au surface electrodes and an introduced Ag|AgCl reference electrode (Ag chlorinated by immersion in 30% 
NaClO for 15 minutes). Measurements were taken using the described in-house electronic control board.
Standard Amperometric Assay. Assays were performed in previously described bespoke measurement 
cells fixed at the PCB surface. Gold electrodes were used to localise cysteinylated Fab′ antibodies via covalent 
thiol linkage directly to the Au surface. Fab′ antibodies were prepared at a concentration of 40 μg/mL in PBS 
and 10 μL incubated overnight in each assay cell at 4 °C. Assay wells were rinsed twice with PBS and 50 μL of 
1% BSA (W:V) in PBS introduced to each well to block exposed hydrophobic surfaces. Blocking was allowed to 
progress for 2 hours at RT. Wells were rinsed twice with PBST (1xPBS, 0.05% tween20 (by volume)) and 20 μL of 
titrated IFNγ was added. The IFNγ titration was prepared in Log2 dilution in PBS across 8 assay points from a top 
concentration of 2 ng/mL. IFNγ incubations were allowed to continue for 1 hour at RT. Wells were washed twice 
with 50 μL PBST and once with 50 μL PBS. Biotinylated detection antibody (R + D Biosystems) was prepared at 
200 ng/mL in PBS and 20 μl added to each well. Incubations were allowed to progress for 1 hour at RT. Wells were 
washed twice with 50 μL PBST and once with 50 μL PBS. Streptavidin::HRP was prepared in PBS at a dilution of 
1:20 from the R + D Biosystems kit stock (no data provided for concentration). 20 μL of streptavidin::HRP work-
ing dilution was added to each well and incubated for 15 minutes at RT. Wells were washed twice with 50 μL PBST 
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and once with 50 μL PBS. TMB substrate was prepared using stock tablets (Sigma-Aldritch T5525) dissolved in 
10 mL of de-ionised water containing 5 μL 30% (by volume) H2O2. Standard buffers (Phosphate-Citrate) were 
omitted from the TMB solution to minimise background electrochemical signal and minimise buffering of rele-
vant electrochemically active species. The enzymatic reaction was allowed to proceed for 20 minutes at RT with 
light excluded. 40 μL samples were measured in bespoke PCB-based cells consisting of an internally fabricated 
PMMA well (50 μL total volume) over two Au surface electrodes and an introduced Ag|AgCl reference electrode 
(Ag chlorinated by immersion in 30% NaClO for 15 minutes). Amperometric measurements were taken using 
the described in-house electronic control board providing a reference electrode bias of −300 mV. Colorimetric 
analysis was conducted using a Promega GloMax spectrophotometer recording at 450 nm.
High-Sensitivity Amperometric Assay. High-sensitivity assays were performed in standard Nunc 
Maxisorp 96-well plates. Fab′ antibodies were localised at the well surface via hydrophobic partitioning. Fab′ 
antibodies were prepared at a concentration of 2 μg/mL in PBS and 50 μL incubated overnight in each assay well 
at 4 °C. Assay wells were rinsed twice with PBS and 300 μL of 1% BSA (W:V) in PBS introduced to each well to 
block exposed hydrophobic surfaces. Blocking was allowed to progress for 2 hours at RT. Wells were rinsed twice 
with PBST (1xPBS, 0.05% tween20 (by volume)) and 60 μL of titrated IFNγ was added. The IFNγ titration was 
prepared in Log1.5 dilution in PBS across 7 assay points and one blank from a top concentration of 120 pg/mL. 
IFNγ incubations were allowed to continue for 1 hour at RT. Wells were washed twice with PBST and once with 
PBS. Biotinylated detection antibody (R + D Biosystems) was prepared at 200 ng/mL in PBS and 70 μL added to 
each well. Incubations were allowed to progress for 1 hour at RT. Wells were washed twice with PBST and once 
with PBS. Streptavidin::HRP was prepared in PBS at a dilution of 1:20 from the R + D Biosystems kit stock (no 
data provided for concentration). 80 μL of streptavidin::HRP working dilution was added to each well and incu-
bated for 15 minutes at RT. Wells were washed twice with PBST and once with PBS. TMB substrate was prepared 
using stock tablets (Sigma-Aldritch T5525) dissolved in 10 mL of de-ionised water containing 5 μL 30% (by vol-
ume) H2O2. Standard buffers (Phosphate-Citrate) were omitted from the TMB solution to minimise background 
electrochemical signal and buffering of relevant electrochemically active species. The enzymatic reaction was 
allowed to proceed for 20 minutes at RT with light excluded. 30 μL samples were measured in bespoke PCB-based 
cells consisting of an internally fabricated PMMA well (50 μL total volume) over two Au surface electrodes 
and an introduced Ag|AgCl reference electrode (Ag chlorinated by immersion in 30% NaClO for 15 minutes). 
Amperometric measurements were taken using the described in-house electronic control board providing a ref-
erence electrode bias of −300 mV. Colorimetric measurements were taken using a Nanodrop spectrophotometer.
Assay in Plasma Matrix. The assays conducted under plasma sample matrix were performed using the 
same protocol applied to standard assays in PBS with the exception that IFNγ standards were diluted into plasma.
Sensor Characterisation. 40 μL of 1 M NaCl was used as a reference sample in each of five previously 
described bespoke electrochemical measurement cells. The described in-house control board supplying a refer-
ence electrode bias of −300 mV was used to collect amperometric data over an extended measurement period of 
400 s.
The 16-channel Bio-Instrumentation Board. A custom-made, 4 layer Printed Circuit Board (PCB) has 
been designed and fabricated for the appropriate biasing of the PCB-based amperometric sensor and for the 
concurrent amperometric signal detection (see Fig. 8). The bioinstrumentation board is providing 16 current 
input channels (where working electrodes are connected) and 32 reference and counter electrode connections (16 
connectors each). The captured input current is converted into a voltage signal using standard transimpedance 
amplifier topologies (LTC2055 operational amplifier from Linear Technologies) with high accuracy feedback 
resistors (0.1% tolerance) and is filtered from high-frequency noise components using appropriate value capac-
itors. Subsequently, two, fully-differential eight channel, 16-bit resolution voltage-input Analogue-to-Digital 
Converters (ADCs) ADS1198 (Texas-instruments) are employed for the digitisation of the incoming voltage 
signals23. The ADCs are operating with bipolar power supply (±2.5 V) and therefore, are able to detect both 
reduction and oxidation reaction currents. The overall design of the board revolves around the idea of imme-
diate digitisation of the analog biosensor signals, process them by means of standard Digital Signal Processing 
(DSP) techniques and finally send them to the user in digital form either to a PC or to the embedded on-board 
TFT touch screen24, 25. The appropriate biasing voltages for the reference electrodes are provided by a two-wire 
interface, 12-bit, single channel Digital-to-Analog Converter (DAC), the AD5321 (Analog Devices) coupled with 
an OP295 (Analog Devices) operational amplifier-based circuit topology, which allowed bipolar operation of 
the DAC. Finally, 4 high-precision, bipolar power supply, low offset voltage quad amplifiers LMP7704 (Texas 
Instruments) have been placed as potentiostats for the three-electrode amperometric measurement. The total cur-
rent consumption of the electrical platform does not exceed 80 mA, which translates into an ~30 h full operation 
from a low-cost commercially available 3.7 V, 2500 mAh Li-Ion rechargeable battery.
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